Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients who used adjuvant Keytruda had a reduced risk of recurrence and a 38% lower risk of death.
Following a single dose of Keytruda, scans were able to show metabolic changes in tumors that correlated with longer survival.
The combination regimen improved overall survival by more than 50% compared with chemotherapy.
Adding a personalized cancer vaccine to a checkpoint inhibitor lowered the risk of recurrence or metastasis by about half.
Real world data are encouraging regarding immunotherapy to treat metastatic lung cancer across racial and ethnic groups.
Treatment was generally safe, but side effects were common.
The FDA recently approved Keytruda for the treatment of non-small-cell lung cancer before and after surgery.
New therapies tested delayed relapse and, in some cases, lengthened survival, for women with cervical, ovarian and endometrial cancers.
A UCSF trial tests precision radiation with immunotherapy as new treatment for advanced cases of metastatic prostate cancer.
Adjuvant immunotherapy can help reduce the likelihood of the skin cancer returning, but is more better or is less more?
Shivani Srivastava receives NCI MERIT Award to investigate how to improve engineered cancer immunotherapies against solid tumors.
Adding checkpoint inhibitors to chemotherapy before surgery and continuing them alone afterward reduces the risk of recurrence and death.
A chemotherapy-free regimen combining immunotherapy with an antibody-drug conjugate extended survival by 15 months.
The checkpoint inhibitor is now indicated for pre- and post-surgery treatment of Stage II or III non-small-cell lung cancer.
Other studies focused on bladder cancer, prostate cancer and liquid biopsies.
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.